The Integris Medtech IPO has been announced and its dates are awaited, with the shares to list on the NSE and BSE. The issue size is ₹600 crore. Kfin Technologies Ltd is the registrar to the issue, and Axis Capital Pvt.Ltd., Citigroup Global Markets India Pvt.Ltd., ICICI Securities Ltd., IIFL Capital Services Ltd are the lead managers.
Founded in 2008, Integris Medtech Ltd is an India based international company which manufactures and provides global medical products and laboratory solutions for medical products and laboratory solutions. The company designs, manufactures, markets, and distributes an extensive range of medical devices and solutions that include cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. Integris Medtech has operations located in India, Germany, and the Netherlands.
It sells its product line in more than 65 international markets in India, Europe, and Southeast Asia. The company's customer segment comprises of more than 9,500 laboratories and 2,000 hospitals and cathlabs and a portfolio of over 22,000 SKUs with more than 200 brands of laboratory and cardiovascular segments. The core divisions of the company's operations include: Cardiovascular Devices – including drug eluting stents, drug coated balloons, advanced coronary interventions and vascular access.
Laboratory Solutions – including clinical, research, and industrial laboratory devices, reagents, and consumables, as well as instrumentation service such as installation, maintenance and calibration via its BioCal product line. The firm caters to laboratories and hospital facilities situated in India, Singapore, Thailand, Malaysia, and the Philippines, serving the government sector as well as private sector entities.
European operations of the company deal mostly with products used in cardiology, which include its own product range, namely the Chrome and Protégé series of instruments. By June 30, 2025, Integris Medtech boasted 1,879 employees, which were sales, service, and application experts. Moreover, more than 15,000 patients were supported by the company through more than 100 clinical trial sites in various parts of the world.
As described in the offer document.
Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh, Punita Sharma.
Work out the listing gain for this IPO
Applications are made through ASBA, where the money is blocked in your own bank account rather than paid, or through a UPI mandate for applications up to five lakh rupees. Through your broker's app, choose the issue, the number of lots and the price; bid at the cut-off price so that the application is valid whatever price the issuer finally fixes; and approve the UPI mandate that arrives from your bank.
Through net banking, the ASBA form in your bank's IPO section does the same without a broker. One application per PAN counts; a second application in the same name is rejected, though applications in family members' names with their own PANs and demat accounts are separate.
Retail applications are capped at two lakh rupees; above that you apply as a non-institutional investor, where allotment is proportionate rather than by lottery. The money stays in your account and earns interest until allotment, and the block is released on the allotment date if you receive nothing.
The expected listing premium, usually called the grey market premium, is the amount per share that unofficial dealers are quoting for the issue before it lists. It is a sentiment reading, not a price you can transact at, and it is not regulated by SEBI or the exchanges. It moves through the day, usually tracks subscription, and often changes sharply in the final hours before listing.
Rupix records every observation and shows the trend, as a percentage of the top of the price band so that issues of different sizes can be compared. It is one input, alongside subscription, the company's financials and the valuation the issue asks for, and it does not predict the listing price.
The issue size is ₹600 crore.
On the registrar's website at https://ipostatus.kfintech.com/, by PAN, application number or demat account, once the basis of allotment is published. The Rupix app can also check it by PAN.
Through your broker's app with a UPI mandate, or through your bank's net banking using ASBA. Bid at the cut-off price, approve the mandate, and the money stays blocked in your account until allotment. Rupix does not take applications.